ABSTRACT
COVID-19-caused neurological problems are the important post-CoV-2 infection complications, which are recorded in ~ 40% of critically ill COVID-19 patients. Neurodegeneration (ND) is one of the most serious complications. It is necessary to understand its molecular mechanism(s), define research gaps to direct research to, hopefully, design new treatment modalities, for predictive diagnosis, patient stratification, targeted prevention, prognostic assessment, and personalized medical services for this type of complication. Individualized nano-bio-medicine combines nano-medicine (NM) with clinical and molecular biomarkers based on omics data to improve during- and post-illness management or post-infection prognosis, in addition to personalized dosage profiling and drug selection for maximum treatment efficacy, safety with least side-effects. This review will enumerate proteins, receptors, and enzymes involved in CoV-2 entrance into the central nervous system (CNS) via the blood-brain barrier (BBB), and list the repercussions after that entry, ranging from neuroinflammation to neurological symptoms disruption mechanism. Moreover, molecular mechanisms that mediate the host effect or viral detrimental effect on the host are discussed here, including autophagy, non-coding RNAs, inflammasome, and other molecular mechanisms of CoV-2 infection neuro-affection that are defined here as hallmarks of neuropathology related to COVID-19 infection. Thus, a couple of questions are raised; for example, "What are the hallmarks of neurodegeneration during COVID-19 infection?" and "Are epigenetics promising solution against post-COVID-19 neurodegeneration?" In addition, nano-formulas might be a better novel treatment for COVID-19 neurological complications, which raises one more question, "What are the challenges of nano-bio-based nanocarriers pre- or post-COVID-19 infection?" especially in the light of omics-based changes/challenges, research, and clinical practice in the framework of predictive preventive personalized medicine (PPPM / 3P medicine).
ABSTRACT
The antimicrobial resistance (AMR) crisis is referred to as ‘Medical Climate Crisis’. Inappropriate use of antimicrobial drugs is driving the resistance evolution in pathogenic microorganisms. In 2014 it was estimated that by 2050 more people will die due to antimicrobial resistance compared to cancer. It will cause a reduction of 2% to 3.5% in Gross Domestic Product (GDP) and cost the world up to 100 trillion USD. The indiscriminate use of antibiotics for COVID-19 patients has accelerated the resistance rate. COVID-19 reduced the window of opportunity for the fight against AMR. This man-made crisis can only be averted through accurate actionable antibiotic knowledge, usage, and a knowledge driven Resistomics. In this paper, we present the 2AI (Artificial Intelligence and Augmented Intelligence) and 7D (right Diagnosis, right Disease-causing-agent, right Drug, right Dose, right Duration, right Documentation, and De-escalation) model of antibiotic stewardship. The resistance related integrated knowledge of resistomics is stored as a knowledge graph in a Neo4j properties graph database for 24 × 7 access. This actionable knowledge is made available through smartphones and the Web as a Progressive Web Applications (PWA). The 2AI&7D Model delivers the right knowledge at the right time to the specialists and non-specialist alike at the point-of-action (Stewardship committee, Smart Clinic, and Smart Hospital) and then delivers the actionable accurate knowledge to the healthcare provider at the point-of-care in realtime. © 2021, Springer Nature Switzerland AG.